<table id="table6" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6: Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of INTELENCE<sup>®</sup>
</caption>
<col align="left" span="1" valign="top" width="17%"></col>
<col align="center" span="1" valign="top" width="17%"></col>
<col align="center" span="1" valign="top" width="10%"></col>
<col align="center" span="1" valign="top" width="14%"></col>
<col align="center" span="1" valign="top" width="14%"></col>
<col align="center" span="1" valign="top" width="14%"></col>
<col align="center" span="1" valign="top" width="14%"></col>
<tbody>
<tr>
<th colspan="1">Co-administered Drug</th>
<th colspan="1">Dose/Schedule of Co-administered Drug</th>
<th colspan="1">N</th>
<th colspan="1">Exposure</th>
<th colspan="3">Mean Ratio of<br/>
<content stylecode="underline">Co-administered Drug</content>
<br/>Pharmacokinetic Parameters<br/>90% CI; No effect = 1.00</th>
</tr>
<tr>
<th colspan="1">C<sub>max</sub>
</th>
<th colspan="1">AUC</th>
<th colspan="1">C<sub>min</sub>
</th>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With HIV Protease Inhibitors (PIs)</content>
</td>
</tr>
<tr>
<td>Atazanavir</td>
<td>400 mg q.d.</td>
<td>14</td>
<td>↓</td>
<td>0.97<br/> (0.73–1.29)</td>
<td>0.83<br/> (0.63–1.09)</td>
<td>0.53<br/> (0.38–0.73)</td>
</tr>
<tr>
<td>Atazanavir/<br/> ritonavir</td>
<td>300/100 mg q.d.</td>
<td>13</td>
<td>↓</td>
<td>0.97<br/> (0.89–1.05)</td>
<td>0.86<br/> (0.79–0.93)</td>
<td>0.62<br/> (0.55–0.71)</td>
</tr>
<tr>
<td>Darunavir/<br/> ritonavir</td>
<td>600/100 mg b.i.d.</td>
<td>15</td>
<td>↔</td>
<td>1.11<br/> (1.01–1.22)</td>
<td>1.15<br/> (1.05–1.26)</td>
<td>1.02<br/> (0.90–1.17)</td>
</tr>
<tr>
<td>Fosamprenavir/<br/> ritonavir</td>
<td>700/100 mg b.i.d.</td>
<td>8</td>
<td>↑</td>
<td>1.62<br/> (1.47–1.79)</td>
<td>1.69<br/> (1.53–1.86)</td>
<td>1.77<br/> (1.39–2.25)</td>
</tr>
<tr>
<td>Lopinavir/<br/> ritonavir 														<br/>(tablet)</td>
<td>400/100 mg b.i.d.</td>
<td>16</td>
<td>↔</td>
<td>0.89<br/>(0.82–0.96)</td>
<td>0.87<br/>(0.83–0.92)</td>
<td>0.80<br/>(0.73–0.88)</td>
</tr>
<tr>
<td>Saquinavir/<br/> ritonavir</td>
<td>1000/100 mg b.i.d.</td>
<td>15</td>
<td>↔</td>
<td>1.00<br/> (0.70–1.42)</td>
<td>0.95<br/> (0.64–1.42)</td>
<td>0.80<br/> (0.46–1.38)</td>
</tr>
<tr>
<td>Tipranavir/<br/> ritonavir</td>
<td>500/200 mg b.i.d.</td>
<td>19</td>
<td>↑</td>
<td>1.14<br/> (1.02–1.27)</td>
<td>1.18<br/> (1.03–1.36)</td>
<td>1.24<br/> (0.96–1.59)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</content>
</td>
</tr>
<tr>
<td>Didanosine</td>
<td>400 mg q.d.</td>
<td>14</td>
<td>↔</td>
<td>0.91<br/> (0.58–1.42)</td>
<td>0.99<br/> (0.79–1.25)</td>
<td>N.A.</td>
</tr>
<tr>
<td>Tenofovir disoproxil fumarate</td>
<td>300 mg q.d.</td>
<td>19</td>
<td>↔</td>
<td>1.15<br/> (1.04–1.27)</td>
<td>1.15<br/> (1.09–1.21)</td>
<td>1.19<br/> (1.13–1.26)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With CCR5 Antagonists</content>
</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>300 mg b.i.d.</td>
<td>14</td>
<td>↓</td>
<td>0.40<br/>(0.28–0.57)</td>
<td>0.47<br/>(0.38–0.58)</td>
<td>0.61<br/>(0.53–0.71)</td>
</tr>
<tr>
<td>Maraviroc (when co-administered with darunavir/ritonavir)<linkhtml href="#footnote-3">*</linkhtml>
</td>
<td>150/600/100 mg b.i.d.</td>
<td>10</td>
<td>↑</td>
<td>1.77<br/>(1.20–2.60)</td>
<td>3.10<br/>(2.57–3.74)</td>
<td>5.27<br/>(4.51–6.15)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With Integrase Strand Transfer Inhibitors</content>
</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>400 mg b.i.d.</td>
<td>19</td>
<td>↓</td>
<td>0.89<br/> (0.68–1.15)</td>
<td>0.90<br/> (0.68–1.18)</td>
<td>0.66<br/> (0.34–1.26)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Co-Administration With Other Drugs</content>
</td>
</tr>
<tr>
<td>Artemether</td>
<td>80/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours</td>
<td>15</td>
<td>↓</td>
<td>0.72<br/>(0.55–0.94)</td>
<td>0.62<br/>(0.48–0.80)</td>
<td>0.82<br/>(0.67–1.01)</td>
</tr>
<tr>
<td>Dihydroartemisinin</td>
<td></td>
<td>15</td>
<td>↓</td>
<td>0.84<br/>(0.71–0.99)</td>
<td>0.85<br/>(0.75–0.97)</td>
<td>0.83<br/>(0.71–0.97)</td>
</tr>
<tr>
<td>Lumefantrine</td>
<td></td>
<td>15</td>
<td>↓</td>
<td>1.07<br/>(0.94–1.23)</td>
<td>0.87<br/>(0.77–0.98)</td>
<td>0.97<br/>(0.83–1.15)</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>40 mg q.d.</td>
<td>16</td>
<td>↓</td>
<td>1.04<br/> (0.84–1.30)</td>
<td>0.63<br/> (0.58–0.68)</td>
<td>N.A.</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>2-hydroxy-atorvastatin</td>
<td></td>
<td>16</td>
<td>↑</td>
<td>1.76<br/> (1.60–1.94)</td>
<td>1.27<br/> (1.19–1.36)</td>
<td>N.A.</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>Individual dose regimen ranging from 4/1 mg to 16/4 mg q.d.</td>
<td>16</td>
<td>↓</td>
<td>0.89<br/> (0.76–1.05)</td>
<td>0.75<br/> (0.66–0.84)</td>
<td>0.60<br/> (0.52–0.68)</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>Norbuprenorphine</td>
<td></td>
<td>16</td>
<td>↔</td>
<td>1.08<br/> (0.95–1.23)</td>
<td>0.88<br/> (0.81–0.96)</td>
<td>0.76<br/> (0.67–0.87)</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>500 mg b.i.d.</td>
<td>15</td>
<td>↓</td>
<td>0.66<br/> (0.57–0.77)</td>
<td>0.61<br/> (0.53–0.69)</td>
<td>0.47<br/> (0.38–0.57)</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>14-hydroxy-clarithromycin</td>
<td></td>
<td>15</td>
<td>↑</td>
<td>1.33<br/> (1.13–1.56)</td>
<td>1.21<br/> (1.05–1.39)</td>
<td>1.05<br/> (0.90–1.22)</td>
</tr>
<tr>
<td>Digoxin</td>
<td>0.5 mg single dose</td>
<td>16</td>
<td>↑</td>
<td>1.19<br/>(0.96–1.49)</td>
<td>1.18<br/>(0.90–1.56)</td>
<td>N.A.</td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>0.035 mg q.d.</td>
<td>16</td>
<td>↑</td>
<td>1.33<br/> (1.21–1.46)</td>
<td>1.22<br/> (1.13–1.31)</td>
<td>1.09<br/> (1.01–1.18)</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>Norethindrone</td>
<td>1 mg q.d.</td>
<td>16</td>
<td>↔</td>
<td>1.05<br/> (0.98–1.12)</td>
<td>0.95<br/> (0.90–0.99)</td>
<td>0.78<br/> (0.68–0.90)</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>200 mg q.a.m.</td>
<td>15</td>
<td>↔</td>
<td>0.92<br/>(0.85–1.00)</td>
<td>0.94<br/>(0.88–1.01)</td>
<td>0.91<br/>(0.84–0.98)</td>
</tr>
<tr>
<td>R(-) Methadone</td>
<td>Individual dose regimen ranging from 60 to 130 mg/day</td>
<td>16</td>
<td>↔</td>
<td>1.02<br/> (0.96–1.09)</td>
<td>1.06<br/> (0.99–1.13)</td>
<td>1.10<br/> (1.02–1.19)</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>S(+) Methadone</td>
<td></td>
<td>16</td>
<td>↔</td>
<td>0.89<br/> (0.83–0.97)</td>
<td>0.89<br/> (0.82–0.96)</td>
<td> 0.89<br/> (0.81–0.98)</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>20 mg q.d.</td>
<td>16</td>
<td>↔</td>
<td>1.06<br/> (0.95–1.20)</td>
<td>1.03<br/> (0.90–1.18)</td>
<td>0.87<br/> (0.75–1.02)</td>
</tr>
<tr>
<td>Rifabutin</td>
<td>300 mg q.d.</td>
<td>12</td>
<td>↓</td>
<td>0.90<br/> (0.78–1.03)</td>
<td>0.83<br/> (0.75–0.94)</td>
<td>0.76<br/> (0.66–0.87)</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>25-<content stylecode="italics">O</content>-desacetylrifabutin</td>
<td>300 mg q.d.</td>
<td>12<br/>
</td>
<td>↓</td>
<td>0.85<br/> (0.72–1.00)</td>
<td>0.83<br/> (0.74–0.92)</td>
<td>0.78<br/> (0.70–0.87)</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>50 mg single dose</td>
<td>15</td>
<td>↓</td>
<td>0.55<br/> (0.40–0.75)</td>
<td>0.43<br/> (0.36–0.51)</td>
<td>N.A.</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>N-desmethyl-sildenafil</td>
<td></td>
<td>15</td>
<td>↓</td>
<td>0.75<br/> (0.59–0.96)</td>
<td>0.59<br/> (0.52–0.68)</td>
<td>N.A.</td>
</tr>
<tr>
<td>Telaprevir</td>
<td>750 mg every 8 hours</td>
<td>15</td>
<td>↓</td>
<td>0.90<br/>(0.79–1.02)</td>
<td>0.84<br/>(0.71–0.98)</td>
<td>0.75<br/>(0.61–0.92)</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>200 mg b.i.d.</td>
<td>14</td>
<td>↑</td>
<td>0.95<br/>(0.75–1.21)</td>
<td>1.14<br/>(0.88–1.47)</td>
<td>1.23<br/>(0.87–1.75)</td>
</tr>
</tbody>
</table>